Non-Small Cell Lung Cancer Clinical Trial
Official title:
Vibration Response Imaging (VRI) in the Preoperative Management in Patients With Non-Small Cell Lung Cancer
The purpose of this study is to assess the correlation of the predicted post-operative lung function with the observed post-operative lung function (FEV1 and DLCO) in patients who underwent surgical resection (FEV1 = Forced expiratory volume in 1-second. DLCO = Diffusion capacity for carbon monoxide. ppo = predicted postoperative.)and versus the gold standard QRRVP (Quantitative Radionuclide Study of Regional Lung Ventilation and Perfusion)
The current standard lung function test uses radioisotopes (materials that produce radiation)
injected in a vein and breathed into the lungs, which can show images of the function of the
lungs.
The VRI system uses pressure sensors that act like electronic stethoscopes (tools used by
doctors to listen to the heart and other sounds in the body). These sensors can record the
energy (vibrations) created by the airflow in the lungs during the breathing process, which
can then be visually imaged.
Before you can start this study, there will be a screening evaluation. The study doctor will
review your medical record to find out if you are eligible to take part in this study.
Information that will be viewed will include whether you have a skin lesion that might
interfere with sensor placement, whether you have a cardiac pacemaker, and/or pregnancy test
results. The study doctor will review with you the other types of information that will be
viewed from your medical record to find out if you are eligible to take part in this study.
For women who are able to have children, if you do not have a negative pregnancy test result
in your medical record, you will not be able to take part in this study.
If you are found to be eligible and you agree to take part in this study, you will have a
lung function test with the VRI system immediately before or after the standard lung function
test. To perform the VRI test, you will be asked to remove your shirt and put on a garment to
cover the front of your body. You will also be asked to remove your jewelry and other body
accessories. You will then be asked to sit on a backless chair, and you will be instructed
how to sit with the proper posture and breathe correctly for this test.
Before recording starts, the sensors will be cleaned and then placed on your back. You will
be instructed to breathe deeply for up to 12 seconds (about 2-3 times), and the vibration
responses will be recorded. You will have a total of 3 recording sessions, one after the
other. Once all the recording is done, the sensors will be removed. The VRI image of the
vibrations will then be examined by the operator in order to check the quality of the image.
The signals recorded from the sensors will be transferred to a computer so that researchers
can study the images. The results of the recordings will be compared with the standard lung
function test results. This will help researchers learn the level of accuracy of the VRI
system in predicting how the lungs will function after surgery.
You will not be told of the results from the VRI testing because the results will not be used
to diagnose your medical condition, nor will any medical decisions be made based on the VRI
results. The VRI system is only used for investigational purposes in this study and will not
replace the current diagnostic methods.
If you undergo surgery, as part of your standard care, you will also return to the clinic for
standard tests to check your lung function 4-12 weeks and 4-12 months after your surgery.
Researchers will compare your pre-surgery test results (both the standard test results and
the VRI results) with the results of the tests after surgery (standard tests) to learn the
level of accuracy of the VRI system in predicting how the lungs will function after surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |